Table 3.
Primary reason for switching therapy by current and most recent past therapy
| Current therapy | Most recent past therapy | Doctor’s recommendation | Side effect profile | Dislike of injections/infusions | Efficacy | Safety | Results of JCV antibody test | Convenience | Cost | Insurance coverage | Nothing else available | Other | Multiple answered | Not answered |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First-line injectable | Any past therapy (n=104)* | 26.0 | 14.4 | 0.0 | 6.7 | 9.6 | 3.8 | 3.8 | 2.9 | 2.9 | 5.8 | 14.4 | 9.6 | 0 |
| First-line injectable | 21 | 12 | – | 4 | 7 | 1 | 4 | 3 | 3 | 5 | 8 | 8 | – | |
| Infusions | 2 | 1 | – | 1 | 2 | 3 | – | – | – | 1 | 4 | 2 | – | |
| Oral therapies | 1 | 2 | – | 2 | – | – | – | – | – | – | 3 | – | – | |
| Other | 3 | – | – | – | 1 | – | – | – | – | – | – | – | – | |
| Infusions | Any past therapy (n=70)* | 28.6 | 1.4 | 2.9 | 31.4 | 2.9 | 2.9 | 1.4 | 0.0 | 0.0 | 1.4 | 11.4 | 12.9 | 2.9 |
| First-line injectable | 20 | 1 | 2 | 17 | 2 | 2 | 1 | – | – | 1 | 7 | 8 | 2 | |
| Infusions | – | – | – | 2 | – | – | – | – | – | – | 1 | – | – | |
| Oral therapies | – | – | – | 1 | – | – | – | – | – | – | – | 1 | – | |
| Other | – | – | – | 2 | – | – | – | – | – | – | – | – | – | |
| Oral therapies | Any past therapy (n=123)* | 22.8 | 8.9 | 25.2 | 9.8 | 2.4 | 2.4 | 6.5 | 0.0 | 0.8 | 3.3 | 4.9 | 13.0 | 0.0 |
| First-line injectable | 20 | 7 | 26 | 9 | 1 | – | 4 | – | 1 | 1 | 2 | 11 | – | |
| Infusions | 6 | 4 | 5 | 1 | 2 | 3 | 4 | – | – | 3 | 3 | 4 | – | |
| Other | 2 | – | – | 2 | – | – | – | – | – | – | 1 | 1 | – |
Note: Data shown as number of subjects (n) except for *percentage of subjects.
Abbreviation: JCV, John Cunningham virus.